Skip to main content
GUANGZHOU WONDFO BIOTECH CO.,LTD logo

GUANGZHOU WONDFO BIOTECH CO.,LTD — Investor Relations & Filings

Ticker · 300482 ISIN · CNE100002102 LEI · 3003000XGXAINFEXYE82 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,834 across all filing types
Latest filing 2026-05-25 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300482

About GUANGZHOU WONDFO BIOTECH CO.,LTD

https://www.wondfo.com.cn

Guangzhou Wondfo Biotech Co., Ltd. specializes in the research, development, and manufacturing of rapid diagnostic products and point-of-care testing (POCT) solutions. The company provides a comprehensive range of diagnostic reagents and instruments across multiple clinical applications, including infectious diseases, cardiovascular health, oncology, diabetes, and pregnancy testing. Its technological capabilities encompass lateral flow assays, fluorescence immunoassays, molecular diagnostics, and chemiluminescence. These platforms support healthcare providers in delivering timely clinical decisions for chronic disease management and emergency diagnostics. With a focus on accessibility and precision, the company supplies diagnostic tools to a global network of medical facilities and laboratories, emphasizing continuous innovation in the field of medical diagnostics.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 92% confidence The document is an official announcement by Guangzhou Wanfu Biological Technology Co., Ltd. detailing the implementation of the 2025 annual equity distribution (dividend): record date, ex-dividend date, dividend per share, total amount, tax handling, and payment methods. This fits the definition of a Notice of Dividend Amount (Code: DIV).
2026-05-25 Chinese
关于调整可转换公司债券转股价格的公告
Capital/Financing Update Classification · 85% confidence The document is a formal corporate announcement detailing the adjustment of the convertible bond (“万孚转债”) conversion price for bond code 123064. It explains the regulatory basis, historical price adjustments, and the new conversion price effective 2026-06-02. This is neither a full financial report nor a regulatory filing for disclosure certifications, but a financing-related update about a debt instrument’s conversion terms. It falls under capital/financing updates (CAP).
2026-05-25 Chinese
关于实施权益分派期间万孚转债暂停转股的提示性公告
Capital/Financing Update Classification · 80% confidence The document is a regulatory announcement by Guangzhou Wanfu Biotechnology regarding a temporary suspension of the conversion rights of its outstanding convertible bonds during an equity distribution period. It details bond codes, suspension dates, and restoration of conversion rights tied to a dividend record date. This is not an earnings release, annual/quarterly report, management change notice, nor a proxy or dividend amount notice per se. Instead, it concerns the capital structure and financing instrument (convertible bonds), fitting the definition of a Capital/Financing Update (CAP).
2026-05-20 Chinese
2025年年度股东会会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is an announcement of the resolutions adopted at the 2025 annual general shareholders meeting, listing detailed vote counts for each proposal. It does not present financial statements or serve as a report itself, but rather publishes official voting results, matching the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-15 Chinese
北京市君合（广州）律师事务所关于广州万孚生物技术股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 80% confidence The document is a legal opinion letter issued by a law firm regarding the procedures and validity of the company’s 2025 annual general meeting. It provides legal analysis of the AGM’s convening, voting process, and resolutions, but it is not itself an annual report, audit report, earnings release, or proxy solicitation. It does not fit any specific financial or governance report category and is instead a compliance/legal filing. Therefore, it should be classified under the fallback category for miscellaneous regulatory/compliance documents: Regulatory Filings (RNS).
2026-05-15 Chinese
华泰联合证券有限责任公司关于广州万孚生物技术股份有限公司2025年度跟踪报告
Regulatory Filings Classification · 80% confidence The document is a "2025年度跟踪报告" issued by the sponsor (Huatai United Securities) on its oversight and follow-up work for Guangzhou Wanf Biotech. It is not the company’s own annual or interim financial report, nor an earnings release, proxy, dividend notice, or other specific event filing. Instead, it is a required regulatory update by the sponsor on governance, disclosure review, on-site inspections, sponsor opinions, and fulfillment of IPO commitments. This falls under the catch-all “Regulatory Filings” category (RNS).
2026-05-11 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.